Key result
Olmesartan dual-combination therapy lowers seated SBP by an additional ~7 mmHg vs monotherapy.
Why the study?
Does olmesartan-based dual-combination therapy improve blood pressure lowering and goal achievement compared to olmesartan monotherapy in adults with hypertension?
Meta-Analysis (n=5,888)
Double-blind
Randomized
Yes
Does olmesartan-based dual-combination therapy improve blood pressure lowering and goal achievement compared to olmesartan monotherapy in adults with hypertension?
Olmesartan-based dual-combination therapy provides superior blood pressure lowering and goal achievement compared to monotherapy across age and CKD subgroups, without increasing adverse events.
Answers are grounded in this paper and cite their sources.
Supports initial olmesartan dual-combination over monotherapy for faster SBP control in hypertension; reinforces guidelines and extends evidence across subgroups.
Antihypertensive monotherapy is often insufficient to control blood pressure (BP). Several recent guidelines advocate for initial combination drug therapy in many patients. This meta-analysis of seven randomized, double-blind studies (N = 5888) evaluated 8 weeks of olmesartan medoxomil (OM)-based single-pill dual-combination therapy (OM+amlodipine/azelnidipine or hydrochlorothiazide) vs OM monotherapy in adults with hypertension. BP-lowering efficacy, goal achievement, and adverse events were assessed in the full cohort and subgroups (elderly/nonelderly and patients with and without chronic kidney disease). In the full cohort at week 8, for dual therapy vs monotherapy, seated BP was lower (137.5/86.1 mm Hg vs 144.4/89.9 mm Hg), and the mean change from baseline in BP and BP goal achievement (<140/90 mm Hg) were greater (-22.7/-15.0 mm Hg vs -16.0/-11.3 mm Hg and 51.2% vs 34.7%, respectively). Adverse events were similar between groups. BP-lowering efficacy among subgroups mirrored the findings in the full cohort whereby changes were significantly greater following OM dual-combination therapy vs OM monotherapy.
No takes yet. Share an insight, caveat, or question.
Deedwania et al. (2017) conducted a meta-analysis in Hypertension (n=5,888). Olmesartan medoxomil-based single-pill dual-combination therapy vs. Olmesartan medoxomil monotherapy was evaluated on Mean absolute change in seated systolic blood pressure (SeSBP) from baseline to end point (week 8) (MD 6.67, 95% CI 5.87-7.46). Olmesartan-based single-pill dual-combination therapy reduced seated systolic blood pressure by an additional 6.67 mm Hg compared to olmesartan monotherapy at 8 weeks in patients with hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: